Centre Leon Berard

This study tests whether adding the immunotherapy drug atezolizumab to standard radiation therapy can shrink soft tissue sarcomas more effectively before surgery. About 62 adults with operable sarcoma will receive different sequences of radiation, atezolizumab, and surgery. The g…

This study tests whether a strong drug (ponatinib) given first for 6 months, followed by a standard drug (imatinib), can help adults with newly diagnosed chronic myeloid leukemia reach a deep remission. The goal is to see if patients can then safely stop all treatment. About 170 …

This study aimed to test the safety and effectiveness of combining two drugs, bemarituzumab and bevacizumab, in people with advanced or metastatic endometrial, ovarian, or cervical cancers that have a specific protein (FGFR2b). The trial was withdrawn before enrolling any partici…

This study tests a treatment called HIFU (high-intensity focused ultrasound) for people with pancreatic cancer that cannot be removed by surgery. The treatment uses sound waves to destroy tumor tissue from inside the body. The trial has two parts: first, checking how safe the pro…

This study tests a combination of two drugs, HDM201 and pazopanib, in people with advanced soft tissue sarcoma that has spread. The goal is to find the safest dose and see if the combo can help control the cancer. About 47 adults with a specific genetic type (P53 wild-type) will …

This study tests whether giving immunotherapy before surgery can help shrink or eliminate tumors in people with a specific genetic marker (MSI/dMMR). It includes 240 adults with localized cancers like colorectal or stomach cancer. The main goal is to see how many patients have no…

This study looks at whether adding pegfilgrastim (a drug that increases white blood cells) to standard chemotherapy and trastuzumab can help the immune system better attack HER2-positive breast cancer. About 90 women with early-stage, operable breast cancer will be randomly assig…

This study tests whether adding an experimental drug called NP137 to standard immunotherapy can help control advanced solid tumors that have stopped responding to treatment alone. About 57 adults with various advanced or metastatic solid tumors will receive NP137 alongside their …

This study looks at whether cancer patients who are not expected to be cured benefit from being referred to a palliative care team when they visit the emergency room. About 240 adults with advanced cancer will be randomly assigned to either standard care or a direct referral to p…

This study follows 500 adults aged 18-65 who finished chemotherapy for certain cancers and are in remission. Over 5 years, researchers will check for 19 possible late side effects like heart problems, memory issues, and fatigue. The goal is to catch these problems early and impro…